Target intelligence / Profile preview

Emerin (EMD)

Target
EMD
Molecular classification
Nuclear membrane protein, LEM-domain protein, Inner nuclear membrane (INM) protein, Nuclear lamina-associated protein
01

Overview

Emerin is a serine-rich nuclear membrane protein consisting of 254 amino acids (∼29 kDa). It contains an N-terminal LEM domain allowing interaction with nuclear lamins and DNA-binding proteins (such as BAF), which is essential for maintaining nuclear architecture and organizing chromatin. Highly expressed in cardiac and skeletal muscle, emerin is crucial for nuclear envelope integrity, regulation of gene expression, and myogenic differentiation. Mutations in the *EMD* gene cause Emery–Dreifuss muscular dystrophy, a rare X-linked disorder characterized by skeletal muscle wasting, joint contractures, and life-threatening cardiac arrhythmias. Emerin interacts with various nuclear proteins (lamins, HDAC3, chromatin modifiers) to coordinate chromatin tethering, gene silencing, and nuclear lamina reformation, especially during cell division and differentiation. Loss of emerin disrupts nuclear mechanics and gene regulation, leading to the pathology noted in EDMD and related conditions.

Other names
EmerinEMDEDMDSTALEM domain-containing 5LEMD5
02

Mechanism of action

Not applicable, as no drugs directly target emerin

03

Biological functions

Maintenance of nuclear envelope structure and integrityTethering/reorganization of chromatin at the nuclear peripheryRegulation of gene expression and chromatin silencingCoordination of cell signaling pathways (including mechanotransduction)Regulation of myogenic differentiation (muscle development)Involvement in nuclear assembly/mitosis
04

Disease associations

Emery–Dreifuss muscular dystrophy (EDMD)Cardiac conduction defectsDilated cardiomyopathyRestrictive dermopathy (progeroid syndromes, rare)
05

Safety considerations

As emerin is not a therapeutic target, safety concerns relate primarily to disease-causing mutations. Loss of emerin function leads to muscle weakness, cardiac arrhythmias, and progressive cardiac failure (in EDMD); no direct therapeutic safety concerns are reported
06

Biomarkers

Mutations or loss of emerin expression in muscle (skeletal or cardiac) may be used for diagnosis of X-linked Emery–Dreifuss muscular dystrophy and related cardiomyopathies; emerin deficiency is a diagnostic biomarker for these conditions

Beyond the preview

Go deeper on Emerin (EMD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emerin (EMD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call